Myocardial Infarction Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Pfizer, Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer I

DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/report-store/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Myocardial Infarction Market Report:
• The Myocardial Infarction market size was valued approximately USD 21 Billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The majority of the 7MM's most diagnosed prevalent cases were found in the United States. In the US, there were 8,038,230 diagnosed prevalent instances of MI in total in 2021
• In November 2022, During the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions, Amgen disclosed end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran. These results were also simultaneously published in the New England Journal of Medicine
• The data readouts from the Phase III (DAPA-MI) study of FARXIGA/FORXIGA are anticipated by 2H 2023, according to AstraZeneca's Q32022 investor presentation. an important regulatory submission estimated to be accepted after 2023
• For the age group >35 years from 2015 to 2035, Kuhn et al. (2022) assessed the prevalence of MI in both men and women. According to the report, there were 519,400 Myocardial Infarction patients hospitalised in France between 2007 and 2015, with a higher percentage of men than women. Men's and women's average ages were 65.0 and 74.9 respectively; 45.8% of Myocardial Infarction hospitalised men were aged 55 to 74
• Germany had the most diagnosed prevalent MI cases among the EU4 nations, whereas Spain had the lowest prevalence rate among the 7MM
• Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
• Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal®, Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others
• The Myocardial Infarction epidemiology based on gender analyzed that the prevalence of myocardial infarction (MI) is more common among males as compared to females
• The Myocardial Infarction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myocardial Infarction pipeline products will significantly revolutionize the Myocardial Infarction market dynamics.

Myocardial Infarction Overview
Myocardial cell death brought on by protracted ischemia is the pathological definition of myocardial infarction (MI). As early as 10 to 15 minutes following the start of ischemia, decreased cellular glycogen, loosened myofibrils, and sarcolemmal disruption are the first ultrastructural alterations noticed.

Get a Free sample for the Myocardial Infarction Market Report
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myocardial Infarction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myocardial Infarction Epidemiology Segmentation:
The Myocardial Infarction market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Myocardial Infarction
• Prevalent Cases of Myocardial Infarction by severity
• Gender-specific Prevalence of Myocardial Infarction
• Diagnosed Cases of Episodic and Chronic Myocardial Infarction

Download the report to understand which factors are driving Myocardial Infarction epidemiology trends @ Myocardial Infarction Epidemiology Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr


Myocardial Infarction Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myocardial Infarction market or expected to get launched during the study period. The analysis covers Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Myocardial Infarction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myocardial Infarction Therapies and Key Companies
• JARDIANCE (empagliflozin): Boehringer Ingelheim/ Eli Lilly
• Pelacarsen: Novartis
• FARXIGA(dapagliflozin): AstraZeneca
• Dutogliptin: Recardio
• Selatogrel: Idorsia Pharmaceuticals
• abciximab: Eli Lilly and Company
• Empagliflozin: Boehringer Ingelheim
• Aliskiren: Novartis
• Eplerenone: Pfizer
• Fulacimstat (BAY1142524): Bayer
• Prochymal®: Mesoblast, Inc.
• Angiomax (bivalirudin) anticoagulant: The Medicines Company
• TNK-tPA: Boehringer Ingelheim
• MCC-135: Mitsubishi Tanabe Pharma
• ATH3G10: Athera Biotechnologies
• RO4905417: Hoffmann-La Roche
• Selatogrel: Idorsia Pharmaceuticals, and others

Discover more about therapies set to grab major Myocardial Infarction market share @ Myocardial Infarction Treatment Market
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myocardial Infarction Market Strengths
• Increasing focus on the secondary preventive measure to avoid recurrent/new events, and lifestyle changes, along with the growing number of smokers and increasing cases of obesity, diabetes, hypertension, and others, are expected to foster the market growth of Myocardial Infarction

Myocardial Infarction Market Opportunities
• Major cost drivers in the 7MM healthcare system are heart attacks and strokes. The volume of the MI market is incredibly large. The patient receives several therapies concurrently. The smallest patient share portion can provide pharmaceutical companies with options worth millions of dollars

Scope of the Myocardial Infarction Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
• Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal®, Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others
• Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies
• Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Myocardial Infarction Market Access and Reimbursement

To know more about Myocardial Infarction companies working in the treatment market, visit @ Myocardial Infarction Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Myocardial Infarction Market Report Introduction
2. Executive Summary for Myocardial Infarction
3. SWOT analysis of Myocardial Infarction
4. Myocardial Infarction Patient Share (%) Overview at a Glance
5. Myocardial Infarction Market Overview at a Glance
6. Myocardial Infarction Disease Background and Overview
7. Myocardial Infarction Epidemiology and Patient Population
8. Country-Specific Patient Population of Myocardial Infarction
9. Myocardial Infarction Current Treatment and Medical Practices
10. Myocardial Infarction Unmet Needs
11. Myocardial Infarction Emerging Therapies
12. Myocardial Infarction Market Outlook
13. Country-Wise Myocardial Infarction Market Analysis (2019-2032)
14. Myocardial Infarction Market Access and Reimbursement of Therapies
15. Myocardial Infarction Market Drivers
16. Myocardial Infarction Market Barriers
17. Myocardial Infarction Appendix
18. Myocardial Infarction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Myocardial Infarction Pipeline https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Myocardial Infarction Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myocardial Infarction market. A detailed picture of the Myocardial Infarction pipeline landscape is provided, which includes the disease overview and Myocardial Infarction treatment guidelines.
Myocardial Infarction Epidemiology https://www.delveinsight.com/report-store/myocardial-infarction-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myocardial Infarction Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Myocardial Infarction epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.